SCHEMBL20695359

SCHEMBL20695359

O=C1CCC2(CN(C(=O)c3cc4cc(OC(F)(F)F)ccc4s3)C2)N1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CHRNA7 P36544 2/20 0.39
▸ CLK1 P49759 2/20 0.38
▸ F2 P00734 1/20 0.36
▸ TPSAB1 Q15661 1/20 0.36
▸ TPSD1 Q9BZJ3 1/20 0.36
▸ TPSG1 Q9NRR2 1/20 0.36
▸ ALDH1A1 P00352 1/20 0.35
▸ HDAC6 Q9UBN7 1/20 0.35
▸ MGLL Q99685 2/20 0.34
▸ ABL1 P00519 1/20 0.34
▸ BCR P11274 1/20 0.34
▸ OPRL1 P41146 2/20 0.34
▸ GAA P10253 1/20 0.34
▸ DRD2 P14416 1/20 0.34
▸ DRD3 P35462 1/20 0.34
▸ GPR183 P32249 1/20 0.34
▸ KCNA5 P22460 2/20 0.33
▸ HTR3A P46098 1/20 0.33
▸ PDK1 Q15118 1/20 0.33
▸ PDK2 Q15119 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20695465 0.87 CLK1 (0.46) CHRNA7CLK1ALDH1A1DRD2DRD3
SCHEMBL20695487 0.85 CHRNA7 (0.44) CHRNA7CLK1ALDH1A1MGLLGAA
SCHEMBL20695448 0.83 MGLL (0.43) CHRNA7ALDH1A1MGLLGAAHTR3A
SCHEMBL20708779 0.82 DYRK1A (0.45) CLK1F2TPSAB1TPSD1TPSG1
SCHEMBL20695161 0.81 LMNA (0.43) CHRNA7CLK1F2TPSAB1TPSD1
SCHEMBL20695284 0.80 MGLL (0.38) ALDH1A1MGLLOPRL1GPR183
SCHEMBL20695172 0.80 HRH4 (0.52) CHRNA7ALDH1A1HDAC6DRD2DRD3
SCHEMBL20695141 0.79 ALDH1A1 (0.59) ALDH1A1GAA
SCHEMBL20695320 0.79 MGLL (0.49) CHRNA7ALDH1A1MGLLGPR183HTR3A
SCHEMBL20695242 0.78 ALDH1A1 (0.36) CHRNA7ALDH1A1MGLLGAAHTR3A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10610520-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2020-04-07 — — US disclosed
US-20190125728-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2019-05-02 — — US disclosed
US-20190125728-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2019-05-02 — — US disclosed
EP-3438109-A1 HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2019-02-06 — — EP disclosed
EP-3438109-A1 HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2019-02-06 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190125728-A1 HETEROCYCLIC COMPOUND MAG, HTT, ACHE CHRNA7 334/4885CLK1 3574/4885F2 3434/4885
US-10610520-B2 Heterocyclic compound MAG, HTT, ACHE CHRNA7 334/4885CLK1 3574/4885F2 3434/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback